Mark Jeffrey DeLong - 13 Jan 2026 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Business & Strat Officer
Signature
/s/ David Watson, attorney-in-fact for Mark DeLong
Issuer symbol
APLS
Transactions as of
13 Jan 2026
Net transactions value
-$39,493
Form type
4
Filing time
15 Jan 2026, 16:33:29 UTC
Previous filing
11 Jun 2025
Next filing
21 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DeLong Mark Jeffrey Chief Business & Strat Officer C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM /s/ David Watson, attorney-in-fact for Mark DeLong 15 Jan 2026 0001856078

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale $39,493 -1,780 -2.1% $22.19 83,058 13 Jan 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 12, 2026.
F2 This includes 893 shares from April 30, 2025 ESPP purchase.